The three clinical trials currently led by STALICLA now on the portal of the World Health Organization (WHO) and of

STALICLA is now enrolling patients with ASD Phenotype 1 in the first interventional trial with STP1 in this biologically-defined subpopulation (NCT04644003). STALICLA is also conducting two observational studies (NCT04600882 and NCT04273087) to identify new subgroups of patients within the autism spectrum. 

Back to News

Search for content on Stalicla...